The Trump administration has selected 15 high-cost drugs, including Trulicity and Biktarvy, for Medicare price negotiations, enabling direct haggling with manufacturers to reduce costs starting in 2028.

The China-ASEAN Regional Medical Products Trading Platform finalized its inaugural 2026 transaction exceeding 10 million yuan between Qilu Pharmaceutical and a Thai buyer, enhancing cross-border pharma trade.

Denmark's Laegemiddelstyrelsen announces the launch of the FAST-EU pilot on January 30, 2026, streamlining procedures for multi-national clinical trials via CTIS to boost EU clinical research efficiency.

Japan's Cabinet Office approves 330 billion JPY package targeting bioclusters, rare disease trials, cell/gene therapy manufacturing, and biosimilars.

All 16 pharmaceutical companies that signed pricing deals with the Trump administration have increased list prices on multiple drugs in January 2026, highlighting tensions in US drug pricing negotiations.[2]

SCIEX announces the localization of its advanced XR QTOF and ZenoTOF analytical systems in China, enhancing access to cutting-edge life science technologies for Asian pharmaceutical R&D and manufacturing.

The newly agreed India-EU Free Trade Agreement eliminates tariffs on pharmaceuticals, enhancing supply chain security and opening Europe's $572.3 billion market to Indian B2B partners in manufacturing, APIs, and contract services.

Atradius forecasts robust 6.6% growth in Chinese pharmaceuticals production for 2026, fueled by biopharma innovations, R&D investments, and policy support amid Asia's leading regional expansion.

The European Parliament has adopted key proposals under the Critical Medicines Act to enhance EU pharmaceutical supply resilience, prioritize local production, and address shortages of essential drugs like antibiotics and insulin.

The EU Parliament has agreed on clear priorities for negotiations on the Critical Medicines Act, emphasizing investments in pharmaceutical manufacturing capacity to strengthen Europe's strategic autonomy in critical drug production.